Get the Stockscreener App
1.27
2.42%
0.03
Geron Corp stock is traded at $1.27, with a volume of 8.29M.
It is up +2.42% in the last 24 hours and down -27.01% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.24
Open:
$1.23
24h Volume:
8.29M
Relative Volume:
0.57
Market Cap:
$840.72M
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-3.9688
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
-2.31%
1M Performance:
-27.01%
6M Performance:
-68.72%
1Y Performance:
-65.49%
1-Day Range:
$1.20
$1.28
1-Week Range:
$1.17
$1.39
52-Week Range:
$1.17
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.27 | 840.72M | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - GlobeNewswire Inc.
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Is Geron Corp. (NASDAQ:GERN) the Most Promising Penny Stock According to Analysts? - Insider Monkey
11 Most Promising Penny Stocks According to Analysts - Insider Monkey
Contact The Gross Law Firm by May 12, 2025 Deadline to Join Class Action Against Geron Corporation (GERN) - GlobeNewswire
Geron Shareholder Sues Executives Over Drug Launch Misrepresentations - USA Herald
Geron Shareholder Sues Execs Over Drug Launch Claims - Law360
Geron stock hits 52-week low at $1.19 amid sharp annual decline By Investing.com - Investing.com South Africa
Geron Brass Sued Over Cancer Drug Prospects After 32% Stock Drop - Bloomberg Law News
Geron stock hits 52-week low at $1.19 amid sharp annual decline - Investing.com India
Is Geron Corp. (NASDAQ:GERN) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire
GERN Investors are Reminded of an Opportunity to Lead Geron Corp - GuruFocus
Geron (GERN) to Announce Q1 Financial Results - GuruFocus
Geron Corporation (GERN) Faces Significant Stock Decline Amidst Volatility - GuruFocus
2025-04-13 | Shareholders that Lost Money on Geron Corporation (GERN) Should Contact Levi & Korsinsky About Pending Class ActionGERN | NDAQ:GERN | Press Release - Stockhouse
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - GlobeNewswire
Geron Corp (GERN) Reports Q3 2023 Financial Results and Business Highlights - GuruFocus
Geron stock touches 52-week low at $1.27 amid market challenges - Investing.com
Geron's SWOT analysis: biotech firm's stock faces growth hurdles amid promising drug developments - Investing.com
Geron’s SWOT analysis: biotech firm’s stock faces growth hurdles amid promising drug developments - Investing.com Canada
Should You Invest in Geron Corporation (GERN)? - MSN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron LawsuitGERN - PR Newswire
GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Geron - GlobeNewswire
GERN INVESTOR DEADLINE: Geron Corporation Investors with Substan - GuruFocus
GERN INVESTOR DEADLINE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - The Victoria Advocate
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XPLR, Geron, enCore, and Fluence and Encourages Investors to Contact the Firm - GlobeNewswire
Geron stock touches 52-week low at $1.46 amid market challenges - Investing.com
GERN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments (GERN) - Seeking Alpha
Geron Q1 2025 Earnings: Complete Coverage of May 7 Financial Results and Conference Call - Stock Titan
Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025 - Yahoo Finance
Geron Corporation's (NASDAQ:GERN) Profit Outlook - simplywall.st
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - GlobeNewswire
GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights - PR Newswire
GERN INVESTOR ALERT: Geron Corporation Investors with Substantia - GuruFocus
GERN INVESTOR ALERT: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
When Can We Expect A Profit From Geron Corporation (NASDAQ:GERN)? - Yahoo Finance
Lawsuit filed for Investors who lost money with shares of Geron Corporation (NASDAQ: GERN) - openPR.com
GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit - MarketScreener
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):